Publication details
Cenobamát
| Title in English | The Cenobamate |
|---|---|
| Authors | |
| Year of publication | 2022 |
| Type | Article in Periodical |
| Magazine / Source | Ceska a slovenska neurologie a neurochirurgie |
| MU Faculty or unit | |
| Citation | |
| Web | https://www.csnn.eu/casopisy/ceska-slovenska-neurologie/2022-5-7/cenobamat-132519 |
| Keywords | cenobamate; epilepsy; pharmacoresistance; adjunctive treatment |
| Description | Cenobamate (CNB) is a novel antiepileptic drug with a dual mechanism of action indicated for the adjunctive treatment of focal-onset seizures in adult patients with epilepsy inadequately controlled despite prior treatment with at least two antiepileptic drugs. In therapeutic doses, it most likely acts through positive allosteric modulation of gamma-aminobutyric acid type A (GABAA) receptors at the non-benzodiazepine binding site, as well as preferential inhibition of persistent sodium currents and enhancement of the deactivated state of voltage-gated sodium channels. Numerous clinical experiences with cenobamate testify to its high effectiveness in terms of achieving seizure -freedom, even in patients who are still drug-resistant. At the same time, CNB appears to be a well -tolerated drug with a minimum of adverse events. However, attention must be paid to potential pharmacokinetic interactions and gradual titration when starting treatment. It is contraindicated in patients with a rare familial occurrence of a short QT interval. Its recommended dosage is 200- 400 mg/ d taken in one daily dose. |